Archive for the Cancer screening category.
The colposcope is not as reliable in ruling out the presence of invasive carcinoma as it is in ruling out cancer of the vagina or cervix. A higher index of suspicion and a large number of biopsies are therefore appropriate in evaluating suspicious vulvar lesions. Canadian viagra without prescription. The difficulty in detecting early invasive cancer of the vulva limits the applicability of laser ablation for management of high-grade or extensive VIN.
The need for radical surgery is based on prognostic factors that are predictive of outcome for invasive carcinoma of the vulva. The detection of nodal metastases during surgical staging is the key finding for determining treatment options. Cialis 20 mg online at cheap pharmacy mall.
The impetus to perform more conservative surgery for invasive cancer has been the realization that radical vulvectomy is associated with severe psychosocial sequelae. When compared with healthy adult women, women who have undergone a vulvectomy report lower levels of sexual arousal and poor body image.
Canadian generic viagra
Screening
No specific screening method is available. The profile of a vulnerable patient should always be considered. The average age at which invasive disease is diagnosed is 65 years. The most frequent symptom is a long history of vulvar itching, and the most common finding is a mass. Less commonly, women present with symptoms such as bleeding, discharge, or even dysuria. On physical examination the lesion is usually raised and appears ulcerated, leukoplakic, or wartlike. Most squamous cell carcinomas are unifocal and occur on the labia majora; however, about 5% are multifocal. Because the etiology of vulvar malignancy remains unknown and no physical features are diagnostic of vulvar carcinoma, it is diagnosed on the basis of biopsy. Most authorities believe that VIN I can be managed expectantly, whereas VIN II-III should be treated.
Clomid online at Canadian health care mall.
A man comes in with symptoms of prostatism. What about prostate specific antigen testing then? Let’s say you decided that you are not necessarily offering testing to all of your patients. But if a man comes in with prostatism, what should you do? Well, I’m sure all of you know that if you referred that patient to a urologist, which is becoming less frequent, at least in my practice, they would do prostate cancer screening on a careful basis. But if you are sitting with a man and you decide you are going to start them on an alpha blocker therapy, titran, should you also, as part of your evaluation, include a PSA test? The PSA in men with benign prostatic hypertrophy is much less, the specificity drops. So you are going to deal with more false positive tests in this population. In the AHCPR guidelines for how should you work up men with prostatism, they do not recommend PSA testing. I happen to do it. I do it especially with my patients saying … let me tell you the discussion that I do, and the real point of this discussion is; there are a lot of patients who are going to develop these problems. It’s unclear, should we screen them. You are supposed to elicit the patient values as to whether you should do the test or not. My discussion with men is to say, “There’s this test I can do that can find out whether you have prostate cancer. If you have a positive test, I’m not sure you’ve got it, but what I would recommend you undergo is a biopsy to see if you have the disease. If you undergo a biopsy and it is positive, it is still not clear whether we should do anything about it. What we do is we look at it under the microscope, and it looked like an angry tumor, we would recommend either radiation therapy or surgical resection. But I’ll tell you, if it looks sort of calm and is just sitting there, we might recommend that we do nothing at all. Now how would you feel if we went through this workup and I looked at you and said, ‘the best treatment may be to do nothing, or to do x-ray therapy, or to do surgery?’ is this still something you want to do?” And that’s actually my way out of the discussion. A surprising number of men still say, “I’d rather know than not know.” A surprising number of men say, “Never mind. Let’s not do it.” But I actually do that discussion with all men. Canadian viagra online.
With my patients who are women between the ages of 40 and 50, I say, “The American Cancer Society recommends that you undergo a mammogram every one to two years. However, the data I read suggested that it won’t necessarily help you live longer by doing that. If you were at standard risk for breast cancer, this decision is really up to you. What would you like to do?” And you need to document that you had that kind of discussion. Because, by the way, you in risk management, meaning malpractice hell, if you at least have a document of such discussion with the patient.
Prostate cancer. The American Cancer Society, which is, by the way, in the business of finding cancer, it has a bias that way – recommends annual screening beginning at the age of 50 for all men. Screening should include digital rectal examination and prostate specific antigen testing. Screening should begin at the age of 40 if you are taking care of an African-American, or if you are taking care of a man who has a positive family history of prostate cancer. These are the recommendations by the U.S. Preventative Health Services task force; they also happen to be the recommendation by the American College of Physicians; that routine screening for prostate cancer with digital rectal exam, or serum tumor markers, or transrectal ultrasound is not recommended. Now, if screening is to be done … it’s interesting, the U.S. Preventative Health Services task force book says, it’s not indicated and there’s no data to support doing it. But if you are going to do it, here’s how you do it. If you are going to do it, use those tests, and you should limit the test to men who you expect to have a life expectancy of greater than 10 years. And at the moment, that means men up to the age of 74. Cheap levitra licensed pharmacy.
The burden here, is it causes 35,000 to 40,000 deaths per year. There is substantial morbidity from the disease. There is a very – for patients who die from this, it can be very painful. Like breast cancer. The problem is that autopsy studies show that there is latent prostate cancer in 9 million men who are autopsied, on a population basis. The prostate specific antigen is a pretty sensitive test, but it may detect patients where the prostate cancer is of uncertain clinical significance. In other words, it may just be there and may not cause the patient a problem. One of the good things about screening for breast cancer is that it is very clear that we should do something about it when we find it. When we find prostate cancer, then we have to decide, is it going to do any thing to this patient or not? Which is a more difficult issue. Canadian pharmacy viagra.
There is no evidence, yet, to determine whether early detection and treatment improves survival. All of the studies that have been done so far, mostly from Sweden and Norway, show that there is no difference in survival in men who undergo surgical procedures or other procedure for prostate cancer, and men who are watched and observed conservatively. For well and moderately differentiated disease, the treatment so far offers little benefit over expectant management. The improved survival for men with early stage disease, that we are beginning to see, may be due to the fact that we are making an earlier diagnosis and we are actually changing the natural history of the disease by observing them longer.
Colorectal cancer. Screening for colorectal cancer is recommended for everyone over the age of 50. Fecal occult blood testing is the major test. It should be done on an annual basis. The best way to do this is not by doing a digital rectal examination and then smearing the stool on a card. It is best done by sending the patient home with three stool hem occult cards and having them mailed back to your office. That’s so there are three different specimens done where the patient is on a special diet prior to doing the test. This is one of the places where the American Cancer Society beat out the Preventative Health Services task force. The ACS has been saying for years and years and years, that all patients should have flexible sigmoidoscopies starting at the age of 50, every two to three years. U.S. Preventive Health Services task force said, no, there’s no data to support that, until their most recent edition where, based on a very good case controlled study which showed a decreased risk of dying from colorectal cancer if a patient had undergone flexible sigmoidoscopy. The recommendation is now to do so. It is unclear what the interval should be. There are some who say between every three to five years. Some, Preventative Health Services task force leaves this unclear, but says perhaps once every ten years would be useful. And, by the way, the different … I don’t do flexible sigmoidoscopy, so I refer to gastroenterologists to do it and each one gives me back a slightly different recommendation on a normal exam, about when the next one should be done. Canadian viagra at Canadian health care.
Of course, if a person has fecal occult blood positive stool, colonoscopy is, I think, considered the community standard for the best follow-up test. Most of us would consider barium enema evaluation or flexible sigmoidoscopy after a known positive occult blood test, to be inadequate. There are some high risk groups. A first degree relative with colorectal cancer; it is unclear, still, if the increased risk of having a first degree relative justifies the use of colonoscopy over other screening methods. That increased risk, though, may justify beginning screening before the age of 50; and many of the members of my group, without data to support this, actually start recommending screening colonoscopy to patients after the age of 40 if there is a first degree relative. There is no data to support that, but at the moment, that is where we are as a community standard. We also believe that you need increased surveillance for patients with familial polyposis, ulcerative colitis, a previous history of known adenomatous polyps, or previous history of colon cancer. If you are watching the literature, it’s also unclear that once you do a … if you do a screening colonoscopy, when should the next one occur. And that is changing from every three to every five, to perhaps every ten years.
Cervical cancer. Regular pap tests are recommended for all women who are sexually active. There is little evidence that annual screening is better than every three year testing. But this is assuming that you are sitting with a patient who is at standard risk, and these are risk factors that do not make you standard risk. So early onset of sexual intercourse, multiple sex partners. One question is to get an agreement as to what does multiple mean. Cialis professional – erectile dysfunction treatment. Is that two, is that three, is that four, is that five partners? Or is it more likely to be the case where you have one partner who has multiple partners, which might be a more significant risk problem. Low socioeconomic status. HIV infection; the recommendation is still every six month pap smears in patients with HIV disease. This is because it is known that human papilloma virus, which is the virus that is known to probably induce cervical cancer, seems to grow faster in patients who are HIV positive. Of course, if there is a previous history of abnormal pap smear, that patient should have ongoing annual exams. The thing we like to argue about is what about patients above the age of 65? Should they be undergoing pap smear screening and how often? By the way, the American College of Obstetrics and Gynecology says, “Yes they should be getting them on an annual basis.” There is no data to support that.
The other question is, what about the indication for pap testing in women who have undergone hysterectomy? There is a recent article in the Journal of American Medical Association looking at a large number of women who had undergone total hysterectomy, meaning that their cervix had been removed along with the uterus, which is the standard procedure now. And it’s been shown that basically if you are doing it, what you are really screening for is vaginal cancer. You are no longer screening for cervical cancer. Vaginal cancer is extraordinarily rare. Random pap smear scrapings of the vaginal mucosa are probably useless for making that diagnosis. So based on data, there’s no reason to do it. By the way, in my group, there’s no data but what we do is if a woman has had all normal pap smears consistently before the age of 65, we would sort of drop down to once every 3-5 years screening women past the age of 65. But if you happen to see, which I still do, every now and then you see a patient who is not … I see her at 67 for her hypertension and then find out that she hasn’t had a pap smear for about 20 years or since the birth of her last child, that patient, I believe in more intensive screening for a few years.
If a woman has a previous history of breast cancer or carcinoma in situ, she is at higher risk. Or if she has had a breast biopsy and was known to have atypical hyperplasia. There are associations with breast cancer; exposure to high dose radiation, late age at first pregnancy, if you haven’t had children, or whatever this means, high socioeconomic status. Women who drink more than one or two drinks per day may also be at slightly higher risk for breast cancer. If the woman is healthy and she drinks more than two drinks a day, that’s a reason to do more intensive breast cancer screening. Female viagra online.
What’s the sensitivity of mammography? It’s 10-15% lower – the overall sensitivity is 75-88% – it’s lower in women age 40-49. The specificity ranges from 98.5 – 83%. Radiologists would say that they use much better radiographic equipment and that they would claim that their sensitivity and specificity rates are much better than these published numbers. The adverse effects of screening is that the false positive rate in women between 40 and 49 is 7-10%. There is also a false positive rate of 4.5 – 8% in women from 50-59, and that rate drops as you rise in age, as breast tissue becomes less and less dense. One of the costs that you need to consider, and what feels like I spend more time doing in my practice, is the increased anxiety that women experience when they require a biopsy.
Routine screening is recommended every one to two years with mammography, for women ages 50-69. For women between 40 and 49, there is conflicting evidence regarding the clinical benefit from mammography. There has only been one trial that really tested well, whether this was effective in women between 40 and 49. The big problem is they don’t show a survival benefit. The tumor biology in women who develop breast cancer before menopause is very different from the tumor biology of women who develop breast cancer when they are 70. In women who develop breast cancer premenopausally, breast cancer then is a more systemic disease. Whereas, in women who develop breast cancer late, it seems to be a more localized disease.
Cheap Nymphomax
There is a survival benefit to doing mammography between 40 and 49. It doesn’t seem to occur until 10 to 12 years after you begin the screening, but there is a survival benefit. It’s about an 18% survival benefit. However, when you start doing mammography between 50 and 60, the survival benefit is 22-25%, but it begins 4-5 years after you begin to do the screening. Survival benefit is 18% and it takes 10 years.
If all we do is make a science-driven decision, along with a cost-driven decision, we would probably not recommend screening women between 40 and 49. The NCI consensus panel said we should not be screening women; we should not recommend screening women between 40 and 49. Canadian pharmacy a lot of medications.
The reasons to screen are that the patient may have the preference. If a woman is at high risk for breast cancer, she should certainly begin mammogram screening. If I have a patient whose sister developed breast cancer at the age of 42, that patient is going to get screened on an annual basis in my practice.
The sensitivity of mammography might improve in the future. Studies are being done about whether MRI would be a better technique, but my sense is that the cost involved would not make it a cost-effective intervention. If the treatment of breast cancer makes this major leap, and it has been making major leaps, perhaps we will decide that the survival benefit would be worthwhile. I’ve said that you should be doing annual or biannual screening for women from 60 to 69. What about women higher than 75? Because actually this is where the majority of breast cancers are. There is a very high burden of disease, and if you expect that the patient has a survival of more than five years. You go ahead and recommend. There is not a strict recommendation for screening, but most practitioners would recommend screening. Within my own group, we believe in annual or biannual screening in all women above the age of 50.